Randomized, Open Label, Multiple-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male Subjects

Inclusion Criteria:

1. Healthy male volunteers, age 20 to 55 years.
2. The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2
3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
2. Glomerular filtration rate is under 60ml/min which is calculated by serum creatinine value.
3. Liver enzyme (AST, ALT) level exceeds one and a half times more than maximum normal range.
4. Systolic blood pressure <90mmHg or Diastolic blood pressure < 60 mmHg, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg(Sitting blood pressure) during the screening procedure.
5. Hypersensitive reactions to metformin ingredient, rosuvastatin ingredient, or other drugs (aspirin, antibiotics ect.) or, history of clinically significant hypersensitive reactions
6. History of drug, medication abuse or Positive urine screen
7. Any systemic prescription drug or oriental medicine treatment within 14 days any systemic over-the-counter drug within 7 days before the first administration of study medication.
8. Participation in another clinical trial within 60 days before the first administration of study medication.
9. Component blood donation within 30 days or whole blood donation within 60 days or transfusions within 30days before the first administration of study medication.
10. Administration of drugs which can inhibit or induce transporter proton pump inhibitor, rifampicin ect. within 30 days before the first administration of study medication.
11. Consumption of more than 140g alcohol per week or impossible of stop drinking during period of subject confinement
12. Smoking more than 10 cigarettes per one day or impossible of stop smoking during period of subject confinement.
13. Positive serum test (HIV, Hepatitis B, Hepatitis C)
14. Hereditary or family history of myopathy or, history of myopathy by drugs
15. Inadequate for the clinical trial by the investigator's decision